×
Guardant Health Inventory 2017-2024 | GH
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Guardant Health inventory from 2017 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
View More
Guardant Health Inventory 2017-2024 | GH
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Guardant Health inventory from 2017 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$173B
Vertex Pharmaceuticals (VRTX)
$129.2B
Bristol Myers Squibb (BMY)
$121.3B
Gilead Sciences (GILD)
$120.8B
CSL (CSLLY)
$91.5B
Regeneron Pharmaceuticals (REGN)
$90.7B
GSK (GSK)
$75.3B
Alnylam Pharmaceuticals (ALNY)
$36.1B
Argenex SE (ARGX)
$35.2B
BioNTech SE (BNTX)
$26.1B
Biogen (BIIB)
$25.1B
Illumina (ILMN)
$24B
BeiGene (BGNE)
$20B
Moderna (MRNA)
$16.5B
Incyte (INCY)
$15.7B
Genmab (GMAB)
$15.4B
Vaxcyte (PCVX)
$12.9B
Insmed (INSM)
$12.8B
BioMarin Pharmaceutical (BMRN)
$12.6B
Bio-Techne Corp (TECH)
$11.9B
Sarepta Therapeutics (SRPT)
$11.3B
Exelixis (EXEL)
$10.3B
Revolution Medicines (RVMD)
$10.2B
QIAGEN (QGEN)
$10.1B
Intra-Cellular Therapies (ITCI)
$9.7B
Exact Sciences (EXAS)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$8.7B
Repligen (RGEN)
$7.8B
Ascendis Pharma (ASND)
$7.8B